Raptor rises as RP103 misses Huntington's endpoint
This article was originally published in Scrip
Raptor Pharmaceutical's RP103 (delayed-release cysteamine) did not meet the primary endpoint in a Phase II/III Huntington's disease clinical trial, but the company's stock still soared 14.9% higher on 20 February.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.